{"id":"NCT02337751","sponsor":"Takeda","briefTitle":"A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants","officialTitle":"A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-10","primaryCompletion":"2017-03-14","completion":"2017-03-14","firstPosted":"2015-01-14","resultsPosted":"2019-02-28","lastUpdate":"2022-03-02"},"enrollment":198,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"TVP-1012 1mg","otherNames":[]}],"arms":[{"label":"TVP-1012 1mg Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.","primaryOutcome":{"measure":"Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)","timeFrame":"Up to 52 weeks","effectByArm":[{"arm":"Placebo + TVP-1012 Group","deltaMin":51,"sd":null},{"arm":"TVP-1012 + TVP-1012 Group","deltaMin":91,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":56,"countries":["Japan"]},"refs":{"pmids":["30689042"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":95},"commonTop":["Nasopharyngitis","Fall","Eczema","Contusion","Headache"]}}